PRNewsWire
15 May 2026, 01:53 UTC · 22w ago
Verdict
Headline takes no side. We score ATRA −1.00 across four claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) for Atara's lead product candidate tabelecleucel, preventing its approval in its present form due to manufacturing facility observations.
So whatA CRL for a lead asset derails imminent commercialization and revenue, severely impacting the company's valuation and milestone payment prospects.
More negative than 99% of claims this week
The FDA placed a clinical hold on Atara's active Investigational New Drug (IND) applications due to inadequately addressed GMP compliance issues at the third-party manufacturing facility.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 99% of claims this week
A class action lawsuit alleges Atara made materially false statements by concealing manufacturing issues and ALLELE study deficiencies that made FDA approval of the tabelecleucel BLA unlikely.
More negative than 94% of claims this week
Atara relies significantly on milestone payments from Pierre Fabre for tabelecleucel's commercialization and regulatory approval to fund its operations.
More negative than 90% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a class action lawsuit following an FDA Complete Response Letter and a clinical hold due to manufacturing issues.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
−2.5%
Price agrees with the score
$9.35 vs $9.59 close before publication (May 14) · not market-adjusted
ATRA chart →
